The “Holy Grail” of Lung Cancer Research: Bring the Immune System into Every Tumor
Johan VansteenkisteWith multiple new therapies available, Prof. Johan Vansteenkiste says the search is on for biomarkers to better match patients to treatments. Read more
Could the Daunting Biology of Small-Cell Lung Cancer Provide the Key to Elucidating Drug Resistance?
Fiona BlackhallAt ELCC 2021, Prof. Fiona Blackhall sees hope for improving patients’ poor prognoses on the horizon. Read more
Statistical Design Flexibility Versus Optimism: The Example of KEYNOTE-604
Urania Dafni, ScD+more
In the era of targeted treatments and immunotherapies, it is relatively common to address multiple questions in a single phase III clinical trial. These questions often involve using more than […] Read more
University of California, Davis, Thoracic Oncology Innovation Group to Again Host Latin American Oncologists for 3-Day Preceptorship
David R. GandaraDavid R. Gandara, MD, past-president of the IASLC and director of Thoracic Oncology and senior advisor, UC Davis Comprehensive Cancer Center (UCDCCC), has always had a passion for mentorship, largely […] Read more
Cell-free RNA Affords Another Tool in Lung Cancer Diagnosis and Treatment Monitoring
Kara Nyberg, PhDAlthough cell-free DNA (cfDNA) has emerged as the favored nucleic acid to analyze in liquid biopsy samples, there are situations when this marker fails to provided necessary information. In such cases, cell-free RNA (cfRNA) might help […] Read more
Supporting the Detection of Early-Stage Disease with Use of Biomarkers
Kara Nyberg, PhDThe NELSON trial and the US National Lung Cancer Screening Trial (NLST) marked major advances in lung cancer by establishing that low-dose computed tomography (LDCT) screening of high-risk individuals is effective at catching the disease in early […] Read more
Leveraging ctDNA to Detect Minimal Residual Disease Following Surgery
Kara Nyberg, PhDCurative therapy remains elusive in early-stage NSCLC following surgical resection, sometimes even for patients with stage I disease. Adjuvant therapy can be of benefit, but only for a select few. As shown in the Lung Adjuvant […] Read more
ctDNA Offers a Window Into Emerging Mechanisms of Resistance to Targeted Therapy
Kara Nyberg, PhDTargeted therapy has undoubtedly transformed the treatment landscape for metastatic NSCLC, with multiple agents now available to target seven different molecular drivers. In tandem with the growing treatment armamentarium, comprehensive molecular profiling has been critical in providing insight […] Read more
Dr. Christian Rolfo Previews the New IASLC Consensus Statement on Liquid Biopsy
Joy CurzioIn his keynote address during the IASLC 2020 Hot Topic Meeting: Liquid Biopsy, co-chair Christian Rolfo, MD, PhD, MBA, provided an overview of the fastpaced evolution of liquid biopsy. In 2018, at the time of […] Read more
FDA Perspectives on the Use of Liquid Biopsy in NSCLC
Kara Nyberg, PhDThe US Food and Drug Administration (FDA) recognizes the value of liquid biopsy in managing patients with cancer, and the agency is actively working to bring these assays to the clinic. Harpreet Singh, MD, Director of […] Read more